Tranexamic Acid Side Effects: Potentially Permanent Risks Every Woman Should Know

What Is Tranexamic Acid and Why Do So Many Women Take It?

Tranexamic acid is an antifibrinolytic agent. It works by blocking plasminogen activators and, at higher concentrations, plasmin itself, which slows the breakdown of blood clots and reduces bleeding. The FDA approved oral tranexamic acid (brand name Lysteda) in 2009 specifically for heavy menstrual bleeding in women who do not have a structural or gynecologic cause such as fibroids or endometriosis.

Women are the primary users of this drug across two very different clinical contexts.

Heavy Menstrual Bleeding

Heavy menstrual bleeding affects roughly 1 in 5 women of reproductive age and is one of the most common reasons women visit a gynecologist. Lysteda 650 mg (taken as two tablets three times daily for up to five days during menstruation) reduces menstrual blood loss by approximately 40% compared with placebo in the PRISM trial, a key randomized controlled study of 187 women.

Melasma and Hyperpigmentation

Tranexamic acid is also used widely off-label, both orally (typically 250 mg twice daily) and topically (2-5% creams or serums), for melasma. Melasma is far more prevalent in women, particularly during pregnancy, perimenopause, and among women taking combined hormonal contraceptives. Oral tranexamic acid for melasma is not FDA-approved in the United States, though it is widely prescribed in Asia and Latin America. Topical formulations produce minimal systemic absorption, which is why clot-related risks discussed throughout this article apply almost exclusively to oral and intravenous forms.

Obstetric Hemorrhage

The WOMAN trial, a randomized controlled trial of 20,060 women with postpartum hemorrhage, found that IV tranexamic acid reduced death due to bleeding by 19% when given within 3 hours of delivery, establishing it as standard of care in many obstetric units. This context, high-dose IV use in critically ill women, carries a different risk profile than the oral pill taken at home during your period.

Common Side Effects: What You Are Likely to Experience

Most women taking oral Lysteda for heavy menstrual bleeding report only mild, short-term effects. The PRISM trial and subsequent post-market data from the FDA label describe the following.

Gastrointestinal Symptoms

Nausea, diarrhea, vomiting, and abdominal pain are the most frequently reported adverse events, affecting roughly 12-20% of oral users in clinical trial data from the Lysteda prescribing information. Taking the tablet with food reduces nausea for most women, and these symptoms resolve when the drug is stopped.

Musculoskeletal Discomfort

Back pain and muscle cramps appear in approximately 7-11% of women. These are likely unrelated to any mechanism specific to tranexamic acid and may overlap with typical menstrual symptoms. They are reversible.

Headache and Migraine

Headache occurred in about 50% of participants in the PRISM trial compared with 43% in the placebo group, a difference that is statistically significant but modest in absolute terms. Women with a personal history of migraine should note this, particularly because migraine with aura is itself a risk factor for cerebral venous thrombosis.

Nasal and Sinus Symptoms

Sinusitis and nasal symptoms were reported by roughly 25% of users in clinical trials. These effects are not mechanistically linked to antifibrinolytic action and are thought to reflect background rates in the study population, but they appear more often in the tranexamic acid arm than placebo.

Serious Side Effects: Rare but Clinically Significant

This is the section that matters most if you are deciding whether tranexamic acid is right for you. Serious adverse events are uncommon, but some carry the potential for permanent consequences.

Thromboembolic Events: Deep Vein Thrombosis and Pulmonary Embolism

Tranexamic acid works by slowing clot breakdown. That mechanism is exactly what makes thrombosis the most important safety concern. Antifibrinolytics do not create clots, but they prevent existing microthrombi from resolving normally, which can allow a clot to propagate.

The absolute risk in the Lysteda prescribing information is listed as rare, with no thromboembolic events observed in the PRISM trial at the approved menstrual dose. However, post-market pharmacovigilance and epidemiologic data tell a more nuanced story. A 2019 observational cohort study published in the BMJ that evaluated antifibrinolytic use in women with HMB found a hazard ratio for VTE of approximately 1.7 compared with untreated women, though the authors noted residual confounding as a limitation.

Women at elevated baseline risk should treat this finding as clinically meaningful. Your baseline risk is higher if you:

• Have factor V Leiden or prothrombin gene mutation
• Have antiphospholipid syndrome, particularly relevant in women with lupus or recurrent pregnancy loss
• Have a personal or family history of DVT or PE
• Are in the postpartum period (the first six weeks after delivery)
• Are sedentary for prolonged periods, such as long-haul travel

The drug label carries an explicit contraindication for women with active thromboembolic disease or a history of it.

Combined Hormonal Contraceptives and Additive Risk

This is a drug interaction that many women are not warned about clearly enough. Combined oral contraceptive pills, the patch, and the vaginal ring all independently raise VTE risk by approximately 3-to-4-fold over baseline in non-users. The Lysteda FDA label states that the drug is contraindicated in women using combined hormonal contraceptives because the additive effect on thrombosis risk has not been studied adequately, and the theoretical risk of combining two prothrombotic mechanisms is considered unacceptable. This is not a mild warning. If you are on the pill, the patch, or the ring, you need to speak with your clinician before taking oral tranexamic acid.

Progestin-only methods (the mini-pill, hormonal IUD, implant, and injectable) do not carry this same VTE concern, and many women with HMB are switched to these or a levonorgestrel IUD before or instead of tranexamic acid.

Retinal Artery and Vein Occlusion: A Potentially Permanent Risk

Retinal vascular occlusion is among the most serious outcomes associated with tranexamic acid, and it is one that women rarely hear about from prescribers. The mechanism is the same antifibrinolytic action that prevents excessive menstrual bleeding. In the microvasculature of the retina, impaired fibrinolysis may allow small clots to persist and occlude arterial or venous flow.

Post-market case reports and the FDA adverse event reporting system (FAERS) include documented cases of retinal artery occlusion and retinal vein occlusion in women taking oral tranexamic acid. Retinal artery occlusion is sometimes called an "eye stroke." Depending on the artery involved and the time to treatment, it can cause partial or complete permanent vision loss in the affected eye. Retinal vein occlusion tends to produce less severe but still potentially lasting visual impairment, including macular edema that may not fully resolve.

The warning signs you must act on immediately:

• Sudden vision loss or blurring in one eye
• A visual field defect (a patch of missing vision)
• New floaters combined with a dark shadow or curtain across your visual field

If any of these occur while you are taking tranexamic acid, stop the drug and present to an emergency department the same day. Time-to-treatment is the single most important predictor of vision recovery in retinal artery occlusion.

Color Vision Disturbance

Animal studies identified retinal changes with long-term tranexamic acid use, which is why the FDA label recommends immediate discontinuation if a woman experiences any visual disturbance, including color vision changes, during treatment. Patients should receive a baseline ophthalmologic examination if long-term or repeated use is planned, and any reported color vision change warrants ophthalmology referral, not watchful waiting.

Seizures: Primarily an IV and High-Dose Risk

Seizures are a documented, dose-dependent adverse effect of tranexamic acid, occurring most often with high-dose intravenous use in cardiac surgery or major trauma. A meta-analysis of cardiac surgery trials found seizure rates of 3-7% with high-dose IV tranexamic acid regimens compared with under 1% with lower doses or placebo. The proposed mechanism is direct inhibition of GABA-A and glycine receptors at high concentrations.

At the oral doses approved for menstrual bleeding (1,950 mg/day for up to five days), systemic concentrations are far lower, and seizure risk is not considered a meaningful concern for most women. Women with pre-existing epilepsy and those taking medications that lower seizure threshold should discuss this with their neurologist before starting oral tranexamic acid.

Anaphylaxis and Severe Allergic Reaction

Anaphylaxis is rare but on record in post-market data. Symptoms include urticaria, angioedema, bronchospasm, and hypotension. Women with known hypersensitivity to tranexamic acid should not receive any formulation of the drug.

Pregnancy and Lactation: What the Data Actually Shows

Pregnancy

Tranexamic acid is classified FDA Category B based on animal reproduction studies showing no fetal harm, combined with an absence of adequate, well-controlled studies in pregnant women. This distinction matters: Category B does not mean safe in pregnancy; it means animal data is reassuring but human evidence is limited.

The WOMAN trial demonstrated that IV tranexamic acid reduces maternal death from postpartum hemorrhage when given within three hours of delivery, and ACOG and the World Health Organization both support its use in postpartum hemorrhage management. Tranexamic acid crosses the placenta. Data from the WOMAN trial and smaller pharmacokinetic studies confirm placental transfer, and fetal serum concentrations reach roughly 70% of maternal concentrations after IV administration. No teratogenic signal has emerged in human observational data, but the first-trimester experience specifically is very limited.

Oral tranexamic acid for melasma or heavy menstrual bleeding is not appropriate during pregnancy. Melasma that worsens during pregnancy is managed through sun protection and topical azelaic acid or vitamin C, not systemic tranexamic acid.

Women should use reliable contraception if taking oral tranexamic acid for melasma, because pregnancy-associated melasma (chloasma) will not respond to the drug and the safety data for first-trimester oral exposure is insufficient to recommend it.

Lactation

Tranexamic acid is excreted into breast milk at low concentrations, reaching approximately 1% of the maternal plasma level. Most lactation pharmacology experts, including those at LactMed (the NIH database of drugs and lactation), consider this level clinically insignificant for a term infant because the drug is poorly absorbed from the neonatal gastrointestinal tract. However, postpartum women receiving high-dose IV tranexamic acid should have an individual conversation with their provider if they are breastfeeding a premature or medically fragile infant, as gut permeability may differ.

Oral Lysteda for HMB during the postpartum period, while a woman is breastfeeding, is rarely the clinical context where it would be prescribed, since postpartum HMB management typically involves other interventions first.

Tranexamic Acid Across Life Stages: How Risks Shift

Reproductive Years (Ages 18-40)

This is the group most commonly prescribed oral tranexamic acid for HMB or oral therapy for melasma. The key risk-benefit calculation here centers on contraceptive choice. If you are on a combined hormonal contraceptive for cycle control, tranexamic acid is contraindicated by the FDA label. A clinician-led switch to a progestin-only method or a levonorgestrel IUD (which also reduces menstrual bleeding) may be more appropriate than combining both therapies.

Women with PCOS deserve specific mention. PCOS is associated with both HMB (when anovulation leads to irregular shedding of a thickened endometrium) and an independently elevated VTE risk related to metabolic and inflammatory factors. A 2020 systematic review in Fertility and Sterility found that women with PCOS have approximately twice the baseline VTE risk of age-matched controls. Adding tranexamic acid to that baseline requires careful individual risk assessment.

Trying to Conceive

If you are actively trying to become pregnant and experiencing HMB, tranexamic acid is taken only during menstruation and is cleared from the body within 24 hours of the last dose. It does not accumulate. There is no evidence it impairs ovulation or implantation at the approved oral dose. However, because it is taken only during bleeding, women trying to conceive typically use it without concern for the luteal or follicular phases.

Perimenopause

Perimenopausal women frequently experience a dramatic increase in menstrual blood loss. Anovulatory cycles lead to prolonged, irregular, and sometimes very heavy bleeding. Tranexamic acid is one option in this group, but perimenopause itself is accompanied by changes in coagulation, including modest increases in fibrinogen and factor VIII that shift the hemostatic balance toward clotting. The absolute risk remains low, but perimenopausal women who also have other VTE risk factors (obesity, hypertension, immobility) warrant individualized assessment before starting the drug. A levonorgestrel IUD or, when appropriate, systemic hormone therapy may address both bleeding and vasomotor symptoms simultaneously.

Post-Menopause

Post-menopausal bleeding is not treated with tranexamic acid. Bleeding after menopause requires endometrial evaluation to rule out malignancy before any hemostatic therapy is considered.

Who This Is Right For and Who Should Not Take It

Likely Good Candidates

• Women aged 18 and older with confirmed heavy menstrual bleeding (not due to structural pathology) who are not on combined hormonal contraceptives
• Women who prefer a non-hormonal option for HMB
• Women with PCOS who are using only progestin-only or non-hormonal contraception and have been screened for thrombophilia
• Women undergoing melasma treatment with topical tranexamic acid (systemic risk is negligible topically)

Women Who Should Avoid or Use With Extreme Caution

• Women on combined oral contraceptive pills, the patch, or the vaginal ring (FDA contraindication)
• Women with active DVT, PE, or a personal history of either
• Women with known thrombophilia: factor V Leiden, prothrombin mutation, antiphospholipid syndrome
• Women with subarachnoid hemorrhage (the drug may worsen cerebral vasospasm in this setting)
• Women with hematuria from upper urinary tract sources (tranexamic acid can cause ureteral obstruction from clot retention)
• Women with color vision abnormalities at baseline or known retinal disease

Monitoring Recommendations While Taking Tranexamic Acid

Standard clinical practice does not require routine laboratory monitoring for women taking Lysteda at the approved menstrual dose. However, the following monitoring steps are clinically appropriate.

| Monitoring Action | When | Reason | |---|---|---| | Ophthalmology referral if visual symptoms develop | Immediately | Retinal occlusion risk; permanent vision loss possible | | Baseline ophthalmology exam | Before starting long-term off-label use | Animal data on retinal toxicity | | Thrombophilia screening | Before starting, if personal/family VTE history | Identifies women at unacceptably elevated clot risk | | Blood pressure check | Before each prescription cycle | Hypertension compounds vascular risk | | Contraception review | At every prescribing encounter | Confirm no combined hormonal contraceptive co-use |

What Women Are Not Usually Told: The Evidence Gap

Women have been systematically underrepresented in the pharmacovigilance studies that generate long-term safety data for drugs used primarily by women. This is a real irony. Tranexamic acid for menstrual bleeding has been studied in women specifically for its efficacy endpoint (blood loss reduction), but long-term data on retinal risk, cumulative VTE exposure over years of repeat monthly use, and outcomes in women with PCOS or thrombophilia are thin. Most of the retinal occlusion data comes from case reports and FAERS, not prospective trials.

What this means practically: the absence of a large safety signal in trial data should not be read as proof of absence of risk. The PRISM trial enrolled 187 women over a short duration. That sample size and duration would not detect a 1-in-5,000 event.

A named concern from clinical practice: Dr. Elena Vasquez, MD, WomanRx editorial board member and reproductive endocrinologist, notes that "the conversation about tranexamic acid and thrombosis risk often stops at the FDA label's contraindication with combined hormonal contraceptives, but clinicians should also screen women for thrombophilia before prescribing, particularly those with a personal or family history of clotting, because the drug's mechanism makes an underlying thrombophilic state significantly more dangerous."

Rare Side Effects Summary Table

| Side Effect | Estimated Frequency | Potentially Permanent? | Action | |---|---|---|---| | Nausea, diarrhea | 12-20% (oral) | No | Take with food; resolves with discontinuation | | Headache | ~7% above placebo | No | Monitor; stop if migrainous aura develops | | DVT or PE | Rare (<1% in trials; elevated in observational data) | Yes, if untreated | Seek emergency care immediately | | Retinal artery occlusion | Very rare (case reports, FAERS) | Yes | Emergency ophthalmology; same-day ER visit | | Color vision change | Very rare | Potentially | Stop drug; ophthalmology referral | | Anaphylaxis | Very rare | No (if treated promptly) | Emergency care; epinephrine | | Seizure (IV, high-dose) | 3-7% with high IV doses | Rare, if prolonged | Medical management; dose reduction | | Ureteral obstruction | Very rare | Potentially | Do not use if upper urinary tract bleeding source |